Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer
Phase: Phase 1
Diagnosis: Radiation Oncology, Breast: Early Stage Disease
NCT ID: NCT01477489
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-142
The purpose of this study is to determine the maximum tolerated dose of veliparib that can be given while a patient is receiving radiation therapy.
Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital
Jennifer Bellon, MD,
Dana-Farber Cancer Institute
Alphonse Taghian, MD, PhD,
Massachusetts General Hospital
Brigham and Women's Hospital:
Kristin Roper, 617-525-7387,
Dana-Farber Cancer Institute:
Breast Cancer Nursing Team, 617-632-3478
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
- Histologically confirmed breast cancer with either a) locoregional recurrence after
previous mastectomy or b) inflammatory breast cancer status post mastectomy for which
radiotherapy to the chest wall and regional nodes is planned as part of treatment.
Patients with Stage IV disease are eligible as long as they meet these criteria.
- Surgical resection of disease and willingness to wait at least three weeks after
surgery to begin radiotherapy.
- Willingness to discontinue any cytotoxic chemotherapeutic agents, immunotherapy,
biologic therapy, and targeted therapies (including trastuzumab) at least two weeks
prior to start of radiotherapy.
- Age >18 years.
- ECOG performance status <2 (Karnofsky >60%, see Appendix A).
- Life expectancy of greater than 6 months.
- Adequate hematologic, renal and hepatic function (assessed within the two weeks prior
to registration and within the month prior to the commencement of protocol
- Negative pregnancy test (within two weeks prior to registration) if woman has
child-bearing potential (defined as not having undergone surgical methods of
sterilization and having had menses within the past year).
- Ability to swallow and retain oral medications.
- Willingness to undergo the three required skin punch biopsies for research purposes.
- Ability to understand and the willingness to sign a written informed consent
- Radiation therapy: Prior history of radiation therapy to the chest wall and/or
regional nodes is not allowed (but prior radiation therapy to other sites is
- Breast reconstruction: Patients who have undergone breast reconstruction procedures
after mastectomy are excluded because of concerns about additional toxicity in this
- Gross residual tumor or positive microscopic margins: Patients with gross residual
tumor or positive microscopic margins will not be eligible because radiation dose in
this study will be limited to 60Gy.
- Ongoing therapy with other investigational agents: Patients may not be receiving any
other investigational agents.
- Unresolved toxicity from other agents: Patients with unresolved or unstable, CTCAE
v4 Grade 3 or greater toxicity from prior administration of another investigational
drug and/or prior anti-cancer treatment are not eligible.
- Significant comorbidity: Also ineligible are patients with clinically significant
and uncontrolled major cardiac, respiratory, renal, hepatic, gastrointestinal,
hematologic or neurological/psychiatric disease or disorder, including but not
limited to: active uncontrolled infection; symptomatic congestive heart failure,
unstable angina pectoris, or cardiac arrhythmia; any other illness condition(s) that
could exacerbate potential toxicities, confound safety assessments, require excluded
therapy for management, or limit compliance with study requirements.
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to veliparib.
- Concomitant anti-neoplastic treatment is not allowed during protocol treatment and
should be completed at least 2 weeks prior to commencement of protocol treatment,
with resolution of any associated acute toxicities, except that endocrine therapies
and bisphosphonates are permitted without restriction even during protocol treatment.
- Pregnant women are excluded from this study because radiation therapy has teratogenic
and abortifacient effects. Because there is an unknown but potential risk for
adverse events in nursing infants secondary to treatment of the mother with
veliparib, breastfeeding should be discontinued before the patient receives